Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery
Status:
Recruiting
Trial end date:
2026-02-12
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine
and cisplatin, before surgery works in treating patients with high risk liver cancer
(cholangiocarcinoma) that can be removed by surgery (resectable). Durvalumab is a monoclonal
antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy
drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving durvalumab with gemcitabine and cisplatin before surgery may make the tumor
smaller and reduce the amount of normal tissue that needs to be removed in patients with high
risk resectable cholangiocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Antibodies, Monoclonal Cisplatin Durvalumab Gemcitabine Immunoglobulin G Immunoglobulins